Shanghai Securities News China Securities(Reporter Zhang Xue) On November 10, Gan & Lee Pharmaceuticals...The company announced the transfer of its controlling stake in its wholly-owned subsidiary, GanGan Medical Technology Jiangsu Co., Ltd. (hereinafter referred to as "GanGan Jiangsu"), to Hillhouse Capital.
Founded in 2017, GanGan Jiangsu is an innovation-driven medical technology company specializing in the research and development and production of high-quality drug delivery devices. Leveraging its strong pharmaceutical background and rigorous quality system, the company has established a comprehensive quality management and regulatory compliance system that meets international standards. Its products have obtained certifications from the U.S. Food and Drug Administration (FDA) and the European Union's CE MDR (European Union Medical Device Registration System).(Regulations) certification.
As the transferee, Hillhouse Capital has long focused on investments in the healthcare sector, possessing comprehensive industry chain insights and resource integration capabilities. Leveraging Hillhouse's extensive experience in healthcare industry operations and value enhancement, Gansu will accelerate organizational upgrades, strengthen R&D innovation, build a large-scale, lean manufacturing system, and promote the expansion and deepening of its global customer network, further unleashing its potential and embarking on a new journey of international development.
For Gan & Lee Pharmaceuticals , this transaction will allow the company to further "focus on its core business," "optimize" its non-core assets, and concentrate on innovative drugs in the metabolic fields of diabetes and obesity.Research and development.
Notably, Gan & Lee Pharmaceuticals retained a minority stake in Gan & Lee Jiangsu, creating a "strategic focus + value sharing" structure. It is understood that the equity transfer...The funds will be invested in innovative drug research and development, further consolidating the company's leading position in the field of endocrine and metabolic innovation. Simultaneously, through in-depth cooperation, Gan & Lee's insulin products and Gan & Lee's medical devices can form a "drug-device synergy" closed loop, continuously improving patient treatment convenience.
Gan & Lee Pharmaceuticals stated that this transaction will help the company focus on its core innovative drug business and enhance its core competitiveness. Meanwhile, Hillhouse Capital will leverage its investment ecosystem resources and operational experience in the healthcare sector to further unlock the value of related assets and achieve efficient resource allocation and synergistic development. In the future, the two parties are expected to cooperate in pharmaceuticals, medical devices , and medical services.They actively innovate cooperation models in fields such as [unspecified] to jointly provide more comprehensive health management solutions for diabetic patients.

https://finance.eastmoney.com/a/202511103560019476.html